IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
IRADIMED CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$87.65−0.62 (-0.70%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 49.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
76.7%+2.4 pts over 5 years
Operating margin
31.2%+33.6 pts over 5 years
Net margin
26.8%+22.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +14.4% | +16.3% | +21.5% | +10.2% | |
| Gross profit | +14.2% | +15.9% | +22.2% | +9.6% | |
| Operating income | +19.0% | +18.7% | – | +8.5% | |
| Net income | +16.9% | +20.6% | +75.0% | +11.6% | |
| EPS, diluted | +16.7% | +19.7% | +73.9% | +11.3% | |
| Free cash flow | -2.5% | +23.1% | +26.2% | +8.9% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 22.6% | 2.3% | 24.8% | |
| Return on assets | 19.9% | 2.0% | 21.7% | |
| Current ratio | 9.25 | 12.96 | 7.98 | |
| Inventory turnover | 2.0× | 2.1× | 1.8× | |
| Capex to revenue | 2.4% | 1.4% | 9.3% | |
| Diluted shares | 12M | 12M | 13M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Iradimed generated $85.34M from operations and spent $79.01M on capital expenditure, dividends and share buybacks. 31% of that went back into the business.
Generated
$85.34M
Used
$79.01M
Capital expenditure$24.52M31%Dividends$54.50M69%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin26.8%
×Asset turnover0.81×
×Equity multiplier1.14×
=Return on equity, FY202524.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 26.8% | 0.81× | 1.14× | 24.8% |
| FY2024 | 26.3% | 0.77× | 1.20× | 24.3% |
| FY2023 | 26.2% | 0.74× | 1.22× | 23.7% |
| FY2022 | 24.1% | 0.63× | 1.15× | 17.6% |
| FY2021 | 22.3% | 0.54× | 1.15× | 14.0% |
| FY2020 | 4.3% | 0.46× | 1.18× | 2.3% |
| FY2019 | 25.0% | 0.67× | 1.18× | 19.8% |
| FY2018 | 20.7% | 0.70× | 1.17× | 16.8% |
| FY2017 | 2.2% | 0.61× | 1.18× | 1.5% |
| FY2016 | 22.2% | 0.90× | 1.14× | 22.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$22.48M
- Cash generatingOperating cash flow above zero$24.95M
- Return on assets improvedROA up on the prior year20.9% → 22.9%
- Earnings backed by cashOperating cash flow above net income$24.95M vs $22.48M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.84 → 7.98
- No dilutionShare count did not rise13M → 13M
- Gross margin improvedGross margin up on the prior year76.94% → 76.75%
- More efficientAsset turnover rose0.79 → 0.85